Biogen Idec (BIIB)
$325.93 0.05 (0.02%)
10:23 EST BIIB Stock Quote Delayed 15 Minutes
Previous Close $325.98
Market Cap 68.77B
PE Ratio 23.28
Volume (Avg. Vol.) 365,411
Day's Range 325.40 - 328.13
52-Week Range 215.77 - 374.99
Dividend & Yield N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen Idec News
- From InvestorPlace
- From the Web
If you’re looking for the next big thing in investing, these three down but not out biotech stocks are the way to go.
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
Biogen earnings for the first quarter of 2019 have BIIB stock down on Wednesday despite it beating it estimates for the period.
Smaller-capitalization biotechs can be riskier investments, but EXEL stock has more than just promise off and on the price chart and is readying to be purchased.
Regardless of political risks, there are still valuable opportunities in some healthcare stocks. Here are three to consider.
BIIB stopping its Alzheimer's trials hurt. But for long-term investors, the dip has opened up an opportunity in Biogen stock
The stock charts of T, LOW and MS merit some close technical scrutiny before the trading week comes to a close. Here's what you need to know.
Biogen news about the company's decision to discontinue two Phase 3 Alzheimer’s drug studies is hitting BIIB stock hard on Thursday.
Nightstar Therapeutics stock was soaring on Monday following news that Biogen (BIIB) is acquiring the company for $877 million.
Mizuho Securities has challenged each analyst to select long-term stocks that can provide value. Here are 7 of their top stock picks.
Pharmaceutical stocks have been on the rebound and many are raising their prices this year. What does that mean for business?
These pharma stocks offer low multiples and growth catalysts that could offer relief to investors in the coming year.
The upside case for pharmaceutical stocks is building. The midterm elections results mean its unlikely drug price regulation will happen soon.
Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.
Gilead stock is cheap selling at 11 price-earnings ratio. And it's coming into a long-term support zone. Catch the falling butter knife.
Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.
Biogen reported solid study results for its Alzheimer's study and followed up with a solid quarterly earnings report. BIIB stock is a clear core holding for investors.
From The Motley Fool
From The Motley Fool
From Simply Wall St
We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we’d be remiss not to mention<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/biogen-inc-nasdaqbiib-insiders-increased-their-holdings/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader